

Reference P005

MRL Clinical Study Report, Multicenter Study: A Randomized, Multicenter, Placebo-Controlled, 3-Period, Crossover Study to Assess the Glucose-Lowering Activity, Pharmacokinetics, and Safety and Tolerability of Single Oral Doses of MK-0431 in Patients with Type 2 Diabetes (Protocol 005)

Reference P005
Reports of Human Pharmacokinetic (PK) Studies Patient PK & Initial Tolerability Study Reports

## CLINICAL STUDY REPORT

### MK-0431

**A RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED,  
3-PERIOD, CROSSOVER STUDY TO ASSESS THE GLUCOSE-  
LOWERING ACTIVITY, PHARMACOKINETICS, AND SAFETY  
AND TOLERABILITY OF SINGLE ORAL DOSES OF MK-0431 IN  
PATIENTS WITH TYPE 2 DIABETES**

Generic Name: Generic Name	Protocol 005
Dosage Form: Capsules	Phase I
Indication: Type 2 Diabetes	Study Design: Randomized, Placebo- Controlled, 3-Period Crossover Study
Sponsor Name:	Merck & Co., Inc.
Clinical Monitor:	Gary A. Herman
Study Initiation Date (FPI):	14-Oct-2002
Study Completion Date (LPO):	07-Jan-2003
Investigator Name/Affiliation:	Multicenter (6)
GCP Compliance:	Information regarding GCP compliance can be found in Sections 5.6 and 6.2
Clinical Study Report Date:	07-Nov-2005

## CLINICAL STUDY REPORT

### A Randomized, Multicenter, Placebo-Controlled, 3-Period, Crossover Study to Assess the Glucose-Lowering Activity, Pharmacokinetics, and Safety and Tolerability of Single Oral Doses of MK-0431 in Patients with Type 2 Diabetes (Protocol 005)

## TABLE OF CONTENTS

Contents	Application Starting Page
I. SYNOPSIS	17
II. COMPREHENSIVE STUDY SUMMARY	24
1. Introduction	24
2. Ethics	27
2.1 Ethics Review Committee/Independent Ethics Committee/Institutional Review Board	27
2.2 Ethical Conduct of the Study	27
2.3 Patient Information and Informed Consent Form	27
3. Investigators and Study Administrative Structure	28
4. Study Hypotheses and Objectives	28
5. Investigational Plan	30
5.1 Overall Study Design and Plan: Description	30
5.2 Discussion of Study Design, Including Choice of Control Groups	34
5.3 Selection of Study Population	35
5.3.1 Inclusion Criteria	35
5.3.2 Exclusion Criteria	36
5.3.3 Discontinuation of Patients From Therapy or Study Observation	38
5.4 Treatments	39
5.4.1 Treatments Administered	39
5.4.2 Identity of Clinical Supplies	39

## TABLE OF CONTENTS (CONT.)

Contents	Application Starting Page
5.4.3 Method of Assigning Patients to Treatment Groups	41
5.4.4 Selection of Doses in the Study and Timing of Dose For Each Patients	41
5.4.5 Study Blinding	41
5.4.6 Prior and Concomitant Therapies	42
5.4.7 Treatment Compliance	42
5.5 Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Parameters	43
5.5.1 Measurements Assessed and Timing of Assessment	43
5.5.1.1 Pharmacokinetic Parameters	43
5.5.1.2 Pharmacodynamics	43
5.5.1.3 Safety	44
5.5.2 Primary Response Parameter(s)	46
5.5.3 Drug Concentration and Pharmacodynamic Measurements	47
5.5.3.1 Plasma for MK-0431 and DPP-IV Assay	47
5.5.3.2 Plasma for Active and Total GLP-1 and Incretin Archive	47
5.5.3.3 Plasma for Glucose	48
5.5.3.4 Plasma for Glucose, Insulin and C-Peptide	48
5.5.3.5 Plasma for Glucagon	48
5.5.4 Analytical Measurements	48
5.5.5 Pharmacokinetic Methods	49
5.5.6 Pharmacokinetics/Pharmacodynamics	49
5.6 Data Quality Assurance	51
5.7 Statistical Methods Planned in the Protocol and Determination of Sample Size	51
5.7.1 Statistical and Analytical Plans to Address Study Objectives	51

## TABLE OF CONTENTS (CONT.)

Contents	Application Starting Page
5.7.2 Determination of Sample Size and Power to Address Study Hypotheses	53
5.7.3 Statistical/Analytical Methods and Issues	53
5.7.3.1 Adjustments for Covariates	55
5.7.3.2 Interim Analyses	56
5.7.3.3 Multicenter Studies	56
5.7.3.4 Multiplicity	56
5.8 Changes in the Conduct of the Study or Planned Analyses	56
6. Study Patients and Data Sets Analyzed	57
6.1 Accounting for Patients in the Study	57
6.2 Protocol Deviations	57
6.3 Patients Whose Treatment Was Prematurely Unblinded	58
6.4 Pharmacokinetic, Pharmacodynamic and Safety Populations Analyzed	58
6.5 Demographic and Other Baseline Characteristics	59
6.6 Measurements of Treatment Compliance	69
7. Pharmacodynamic and Pharmacokinetic Evaluation Results	69
7.1 Plasma Glucose	71
7.1.1 Post-OGTT Incremental Glucose AUC	73
7.1.2 Subgroup Analyses	75
7.2 Plasma DPP-IV Activity	75
7.3 GLP-1	77
7.3.1 Active GLP-1	77
7.3.2 Total GLP-1	81
7.3.3 Ratio of Active to Total GLP-1	85
7.4 GIP	89
7.4.1 Active GIP	89

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.